Caring for someone receiving TECVAYLI®

TECVAYLI® is the first treatment of its kind for multiple myeloma—it's called a bispecific antibody, and it works by binding to both multiple myeloma cells as well as T-cells to help the immune system recognize the multiple myeloma cells and destroy them.

What is TECVAYLI® (teclistamab-cqyv)?
TECVAYLI® is a prescription medicine to treat adults with multiple myeloma who:
- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multiple myeloma,
- and
- their cancer has come back or did not respond to prior treatment

TECVAYLI® was approved based on patient responses. There are ongoing studies to confirm the clinical benefit of TECVAYLI®.

It is not known if TECVAYLI® is safe and effective in children.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TECVAYLI®?
TECVAYLI® may cause side effects that are serious, life-threatening, or lead to death, including Cytokine Release Syndrome (CRS) and neurologic problems.

Call your healthcare provider right away if you develop any of the signs or symptoms of CRS or neurologic problems listed below at any time during your treatment with TECVAYLI®:

Cytokine Release Syndrome (CRS). Signs and symptoms of CRS may include:
- fever (100.4°F or higher)
- dizziness or lightheadedness
- confusion or restlessness
- difficulty breathing
- fast heartbeat
- headache
- feeling anxious
- increased liver enzymes in your blood

Please read full Important Safety Information on pages 6-9, and full Prescribing Information, including Boxed WARNING, for TECVAYLI®.
If the person in your care is going through another relapse, it may be time to talk to the doctor about making a change.

There are medicines for relapsed or refractory multiple myeloma that may be able to help manage the person in your care’s disease. Talk to the doctor to see if TECVAYLI® may be a good choice.

IMPORTANT SAFETY INFORMATION (cont’d)

What is the most important information I should know about TECVAYLI®? (cont’d)

Neurologic problems. Symptoms of neurologic problems with TECVAYLI® include:

- headache
- jerking movements
- rigid muscles
- feeling restless
- numbness and tingling (feeling like “pins and needles”)
- confusion
- trouble speaking
- muscle spasms
- tremor
- double vision
- changes in your handwriting
- problems walking
- muscle weakness in your body or face
- hearing loss
- burning, throbbing, or stabbing pain

Please read full Important Safety Information on pages 6-9, and full Prescribing Information, including Boxed WARNING, for TECVAYLI®.
TECVAYLI®, a bispecific antibody, is the first treatment of its kind designed to fight multiple myeloma

TECVAYLI® works by helping the immune system locate the multiple myeloma cells in the body.

One side of TECVAYLI® binds to proteins called BCMA, which are found on multiple myeloma cells (as well as some healthy cells). The other side binds to proteins called CD3, which are found on T-cells.

In doing so, TECVAYLI® is able to activate the T-cells in the immune system to destroy the multiple myeloma cells in the rest of the body.

TECVAYLI® is a kind of medicine called a bispecific antibody, which means that it attaches to 2 different cells

By binding to BCMA and CD3, TECVAYLI® helps the immune system recognize the multiple myeloma cell and destroy it.

TECVAYLI® is a different kind of therapy that may help the person in your care fight their disease.

Results with TECVAYLI®

TECVAYLI® was studied in 110 adults, 78% of whom had already been on at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

More than half of adults saw results with TECVAYLI® in the clinical trial

62% of people in the clinical trial who took TECVAYLI® responded.

28% of people taking TECVAYLI® had a complete response or better to treatment.
29% of people taking TECVAYLI® had a very good partial response, and 5% had a partial response.

Median time to first response with TECVAYLI® was 1.2 months (response times ranged from 0.2 months to 5.5 months).

Talk to the person in your care’s doctor for more information about response.

BCMA, B-cell maturation antigen; CD3, cluster of differentiation 3; CD38, cluster of differentiation 38.

IMPORTANT SAFETY INFORMATION (cont’d)

What is the most important information I should know about TECVAYLI®? (cont’d)

• Due to the risk of CRS and neurologic symptoms, you should be hospitalized for 48 hours after all doses of TECVAYLI®, which are called “step-up doses,” and then you receive the first “treatment dose” of TECVAYLI®.

• After “step-up dose 1” of TECVAYLI®, the dose of TECVAYLI® is increased. After “step-up dose 2,” the dose is increased again when you receive the first “treatment dose” of TECVAYLI®.

• Your healthcare provider will decide when you will receive “step-up dose 2” and your first “treatment dose.”

• “Step-up dose 2” may be given between 2 to 4 days after “step-up dose 1,” or up to 7 days after “step-up dose 1” if you have certain side effects with TECVAYLI®.

• Your first “treatment dose” may be given between 2 to 4 days after “step-up dose 2,” or up to 7 days after “step-up dose 2” if you have certain side effects with TECVAYLI®.

• Your healthcare provider will decide the number of days to wait between your doses of TECVAYLI® as well as how many treatments you will receive.

• If your dose of TECVAYLI® is delayed for any reason, you may need to repeat the “step-up dosing schedule” to receive TECVAYLI®.

• Before each “step-up dose” and your first “treatment dose” of TECVAYLI®, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

Please read full Important Safety Information on pages 6-9, and full Prescribing Information, including Boxed WARNING, for TECVAYLI®.
What is TECVAYLI® (teclistamab-cqyv)?

TECVAYLI® is a prescription medicine to treat adults with multiple myeloma who:
- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and
- their cancer has come back or did not respond to prior treatment

TECVAYLI® was approved based on patient responses. There are ongoing studies to confirm the clinical benefit of TECVAYLI®.

It is not known if TECVAYLI® is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TECVAYLI®?

TECVAYLI® may cause side effects that are serious, life-threatening, or lead to death, including Cytokine Release Syndrome (CRS) and neurologic problems.

Call your healthcare provider right away if you develop any of the signs or symptoms of CRS or neurologic problems listed below at any time during your treatment with TECVAYLI®:

- Cytokine Release Syndrome (CRS). Signs and symptoms of CRS may include:
  - fever (100.4°F or higher)
  - difficulty breathing
  - chills
  - nausea
  - vomiting
  - dizziness or lightheadedness
  - fast heartbeat
  - feeling anxious
  - confusion or restlessness
  - headache
  - increased liver enzymes in your blood

- Neurologic problems. Symptoms of neurologic problems with TECVAYLI® include:
  - headache
  - jerking movements
  - muscle weakness in your body or face
  - numbness and tingling (feeling like “pins and needles”)
  - double vision
  - confusion
  - trouble speaking
  - muscle spasms
  - tremor
  - hearing loss
  - changes in your handwriting
  - problems walking
  - muscle weakness in your body or face
  - hearing loss
  - burning, throbbing, or stabbing pain

Due to the risk of CRS and neurologic symptoms, you should be hospitalized for 48 hours after all doses of TECVAYLI® that are part of the “step-up dosing schedule.” The “step-up dosing schedule” is when you receive the first 2 doses of TECVAYLI®, which are called “step-up doses,” and then you receive the first “treatment dose” of TECVAYLI®. After “step-up dose 1” of TECVAYLI®, the dose of TECVAYLI® is increased. After “step-up dose 2,” the dose is increased again when you receive the first “treatment dose” of TECVAYLI®.

- “Step-up dose 1” is given on day 1 of treatment. “Step-up dose 2” is usually given on day 4 of treatment. The first “treatment dose” is usually given on day 7 of treatment.
  - Your healthcare provider will decide when you will receive “step-up dose 2” and your first “treatment dose.”
    - “Step-up dose 2” may be given between 2 to 4 days after “step-up dose 1,” or up to 7 days after “step-up dose 1” if you have certain side effects with TECVAYLI®.
    - Your first “treatment dose” may be given between 2 to 4 days after “step-up dose 2,” or up to 7 days after “step-up dose 2” if you have certain side effects with TECVAYLI®.
  - Your healthcare provider will decide the number of days to wait between your doses of TECVAYLI® as well as how many treatments you will receive.
  - If your dose of TECVAYLI® is delayed for any reason, you may need to repeat the “step-up dosing schedule” to receive TECVAYLI®.
  - Before each “step-up dose” and your first “treatment dose” of TECVAYLI®, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

- Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with TECVAYLI®, as well as other side effects, and treat you as needed.
- Do not drive or operate heavy or dangerous machinery during and for 48 hours after your TECVAYLI® “step-up dosing schedule” is completed, or at any time during treatment with TECVAYLI® if you develop new neurologic symptoms until the symptoms go away.

TECVAYLI® is available only through the TECVAYLI® and TALVEY™ Risk Evaluation and Mitigation Strategy (REMS) due to the risk of CRS and neurologic problems.

You will receive a Patient Wallet Card from your healthcare provider. Carry the Patient Wallet Card with you at all times and show it to all of your healthcare providers. The Patient Wallet Card lists signs and symptoms of CRS and neurologic problems.

Get medical help right away if you develop any of the signs and symptoms listed on the Patient Wallet Card. You may need to be treated in a hospital.

The care team for the person in your care will enroll in the REMS program and provide them with a Patient Wallet Card to carry with them. They do not need to enroll in the program.

- If you have any questions about TECVAYLI®, ask your healthcare provider.
- Your healthcare provider may temporarily stop or completely stop your treatment with TECVAYLI® if you develop CRS, neurologic problems, or any other side effects that are severe.

See “What are the possible side effects of TECVAYLI®?” for more information about side effects.

Before you receive TECVAYLI®, tell your healthcare provider about all of your medical conditions, including if you:
- have an infection
- are pregnant or plan to become pregnant. TECVAYLI® may harm your unborn baby.
  - Your healthcare provider should do a pregnancy test before you start treatment with TECVAYLI®.
  - You should use effective birth control (contraception) during treatment and for 5 months after your last dose of TECVAYLI®.
  - Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with TECVAYLI®.
- are breastfeeding or plan to breastfeed. It is not known if TECVAYLI® passes into your breast milk.
  - Do not breastfeed during treatment and for 5 months after your last dose of TECVAYLI®.
  - Before each “step-up dose” and your first “treatment dose” of TECVAYLI®, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please read full Important Safety Information on pages 6-9, and full Prescribing Information, including Boxed WARNING, for TECVAYLI®.
How will I receive TECVAYLI®?

• TECVAYLI® will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in your stomach area (abdomen). Your thigh or another area of your body may be injected.

• See “What is the most important information I should know about TECVAYLI®?” at the beginning of this Important Safety Information for information about how you will receive TECVAYLI®.

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. It is important for you to be monitored closely for side effects during treatment with TECVAYLI®.

What are the possible side effects of TECVAYLI®?

TECVAYLI® may cause serious side effects, including:

• See “What is the most important information I should know about TECVAYLI®?”

• Liver problems. TECVAYLI® can cause liver problems that may lead to death. Increased bilirubin and liver enzymes in your blood are common with TECVAYLI® and can also sometimes be severe. These increases in liver enzymes can happen with or without you also having CRS. Your healthcare provider will monitor you for these problems before you start and during treatment with TECVAYLI®. Tell your healthcare provider if you develop any symptoms of a liver problem including:
  – tiredness
  – loss of appetite
  – dark urine
  – yellowing of your skin or white part of your eyes

• Infections. Upper respiratory tract infections and pneumonia are common with TECVAYLI®. TECVAYLI® can cause bacterial and viral infections that are severe, life-threatening, or that may lead to death.
  – Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with TECVAYLI®.
  – Your healthcare provider may prescribe medicines for you to help prevent infections, and treat you as needed if you develop an infection during treatment with TECVAYLI®.
  – Tell your healthcare provider right away if you get a fever, chills, or any signs or symptoms of an infection.

• Decreased white blood cell counts. Decreased white blood cell counts are common with TECVAYLI® and can also be severe. Fever sometimes also happens with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will check your blood cell counts before you start and during treatment with TECVAYLI®, and treat you as needed.

• Allergic reactions and injection site reactions. TECVAYLI® can cause allergic reactions that can affect your whole body (systemic), and also cause injection site reactions.
  – Some people taking TECVAYLI® can develop symptoms of an allergic reaction that can affect their whole body and may include fever or a swollen tongue. Get medical help right away if you develop symptoms of an allergic reaction during treatment with TECVAYLI®.
  – Injection site reactions are common with TECVAYLI® and can include: redness, heat, swelling, bruising, bacterial skin infection (cellulitis), discomfort, blood collection under the skin at the injection site (hematoma), and rash. Tell your healthcare provider if you develop any severe injection site reactions.

Your healthcare provider may temporarily or permanently stop TECVAYLI® if you have any of the side effects listed above and they are severe.

The most common side effects of TECVAYLI® include:

• fever
• pain in your joints and muscles, back and chest muscles, and in your arms and legs
• tiredness and weakness
• upper respiratory tract infections and pneumonia. See “Infections” above.
• nausea
• headache
• diarrhea

The most common severe abnormal lab test results with TECVAYLI® include: decreased white blood cells, red blood cells, and platelets.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please read full Prescribing Information, including Boxed WARNING, for TECVAYLI®.

cp-324738v5

Step-up dosing may help reduce both the chance of getting CRS and the severity of it

TECVAYLI® activates the immune cells to help fight the disease. This activation can cause a serious or life-threatening side effect called Cytokine Release Syndrome (or CRS). The person in your care’s provider will administer premedication and use step-up dosing to decrease the likelihood and severity of CRS. Pretreatment medications may also be needed for doses given after a dose delay.

• Most instances of CRS happened during the first 3 doses
  – 42% of people taking TECVAYLI® experienced CRS after step-up dose 1, 35% after step-up dose 2, and 24% after the initial treatment dose (the third dose)
  – Less than 3% of people taking TECVAYLI® had a first occurrence of CRS after the third dose
• The median time to CRS occurring was 2 days (with a range of 1 to 6 days) after the most recent dose.
  The median amount of time that CRS lasted was 2 days (with a range of 1 to 9 days)

The person in your care’s healthcare team may change the treatment plan if the person in your care experiences side effects.
Starting TECVAYLI®

TECVAYLI® is a ready-to-use treatment

TECVAYLI® is given by a doctor or nurse as a subcutaneous injection under the skin, usually in the stomach area (abdomen), thigh, or another area of the body.

TECVAYLI® starts with what is called “step-up” dosing

Step-up dosing is done with TECVAYLI® to reduce the chance of getting CRS and/or experiencing neurologic symptoms. The amount of TECVAYLI® the person in your care receives will be increased from the first to second dose, and then increased again from the second to third dose. The amount of TECVAYLI® they receive will be based on body weight. The amount given for the third dose will be the same as the ongoing weekly dose. The person in your care should be hospitalized for 48 hours after each dose given during the step-up dosing schedule.

Step-up dosing may be administered in the hospital setting

Step-up dose 2 and/or the first treatment dose may be given between 2 to 4 days* after the previous step-up dose so the healthcare team can manage any side effects.

Step-up dose 1

Step-up dose 2

First treatment dose

Weekly dosing

Step-up dosing schedule

DAY 1

DAY 4

DAY 7

Things to keep in mind as the person you care for starts TECVAYLI®

• Tell the doctor or healthcare provider about any medications the person in your care is currently taking, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements
• Before each step-up dose and the first treatment dose of TECVAYLI®, the person in your care will receive medicines to help reduce the risk and/or lessen the severity of a serious or life-threatening side effect known as CRS
• After the step-up doses, the healthcare provider will decide if the person in your care needs to receive medicines to help reduce the risk of CRS with future doses
• The person in your care should be hospitalized for 48 hours after administration of all doses within the TECVAYLI® step-up dosing schedule

CRS, cytokine release syndrome.

Please read full Important Safety Information on pages 6-9, and full Prescribing Information, including Boxed WARNING, for TECVAYLI®.
The person in your care may need to receive care at more than one treatment center as they start and continue TECVAYLI®

The person in your care should be admitted to the hospital when they start treatment with TECVAYLI®. This is where they should receive their step-up dosing schedule, so that they can be monitored for at least 48 hours after each dose to ensure they are tolerating the treatment. Once the step-up dosing schedule is complete, they will transition to receiving weekly doses of TECVAYLI®, which may be given at a different treatment facility in the outpatient setting.

Here are some tips to keep in mind during transitions in care:

After an initial step-up dosing schedule, TECVAYLI® will be given weekly thereafter, possibly at a different location. The care team can help you and the person in your care set up these appointments, and you may want to consider scheduling the first one before you leave the hospital. It should take place one week after the first treatment dose.

Talk to your care team about when and where the person in your care will receive the initial step-up doses of TECVAYLI®, and where they will receive the ongoing weekly treatment doses. It is very important to have good communication with your care team. If there’s anything you’re unsure about, don’t hesitate to ask.

To help you and the person in your care keep track of treatment, the Starting treatment with TECVAYLI® guide includes a section for you to jot down each time a dose of TECVAYLI® is administered.

It’s also a good idea to keep track of how the person in your care is feeling each day so that you can discuss it with your care team to help them determine whether or not the person in your care is experiencing side effects. You may also want to save important contact numbers in your phone so that you can easily get in touch with your care team if/whenever necessary.

Remind the person in your care to always carry their Patient Wallet Card so that they can be easily identified as someone receiving TECVAYLI®. You may also want to take a picture of it with your cellphone in the event that either of you misplace the card.

IMPORTANT SAFETY INFORMATION (cont’d)

What is the most important information I should know about TECVAYLI® (cont’d)?

• Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with TECVAYLI®, as well as other side effects, and treat you as needed.
• Do not drive or operate heavy or dangerous machinery during and for 48 hours after your TECVAYLI® “step-up dosing schedule” is completed, or at any time during treatment with TECVAYLI® if you develop new neurologic symptoms until the symptoms go away.

TECVAYLI® is available only through the TECVAYLI® and TALVEY™ Risk Evaluation and Mitigation Strategy (REMS) due to the risk of CRS and neurologic problems.

You will receive a Patient Wallet Card from your healthcare provider. Carry the Patient Wallet Card with you at all times and show it to all of your healthcare providers. The Patient Wallet Card lists signs and symptoms of CRS and neurologic problems.

Get medical help right away if you develop any of the signs and symptoms listed on the Patient Wallet Card. You may need to be treated in a hospital.

• If you have any questions about TECVAYLI®, ask your healthcare provider.
• Your healthcare provider may temporarily stop or completely stop your treatment with TECVAYLI® if you develop CRS, neurologic problems, or any other side effects that are severe.

See “What are the possible side effects of TECVAYLI®?” for more information about side effects.

Before you receive TECVAYLI®, tell your healthcare provider about all of your medical conditions, including if you:

• have an infection
• are pregnant or plan to become pregnant. TECVAYLI® may harm your unborn baby.
  – Your healthcare provider should do a pregnancy test before you start treatment with TECVAYLI®.
  – You should use effective birth control (contraception) during treatment and for 5 months after your last dose of TECVAYLI®.
  – Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with TECVAYLI®.
• are breastfeeding or plan to breastfeed. It is not known if TECVAYLI® passes into your breast milk. Do not breastfeed during treatment and for 5 months after your last dose of TECVAYLI®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Preparing for treatment

You can help the person in your care prepare to receive treatment with TECVAYLI®

It might be helpful for them to wear comfortable clothing as the injection site can be located on the stomach area or thigh.

You should also tell the person in your care’s healthcare provider about all of their medical conditions, including if they:

- Have an infection
- Are pregnant or plan to become pregnant. TECVAYLI® may harm their unborn baby
  - Their healthcare provider should do a pregnancy test before they start treatment with TECVAYLI®
  - They should use effective birth control (contraception) during treatment and for 5 months after their last dose of TECVAYLI®
  - They should tell their healthcare provider right away if they become pregnant or think that they may be pregnant during treatment with TECVAYLI®
- Are breastfeeding or plan to breastfeed. It is not known if TECVAYLI® passes into breast milk. They should not breastfeed during treatment and for 5 months after their last dose of TECVAYLI®

Tell the person in your care’s healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Treatment day

You can help by arranging transportation to and from their appointment so that they have the proper time to rest after treatment. Because some people may feel confused after treatment with TECVAYLI®, they should not drive or operate heavy or dangerous machinery during and for 48 hours after the TECVAYLI® “step-up dosing schedule” is completed, or at any time during treatment with TECVAYLI® if they develop new neurologic symptoms until the symptoms go away.

After treatment

Help the person in your care keep track of any side effects they are experiencing by encouraging them to use the symptom tracker in their Starting treatment with TECVAYLI® guide, or you can keep track together. Take a look at the side effects to watch out for on pages 6-9, and report to their healthcare provider any side effects that the person in your care experiences.

Additionally, you can ask the doctor or nurse how to manage any injection site reactions. They can give you tips for how to help with bruising, pain, swelling, or any other reactions after injection. Note down any additional questions you or the person in your care have so you can refer to them at the next appointment.

Community support

There is a lot of support available for patients and their caregivers. Visit TECVAYLI.com to learn about organizations that provide educational materials, host meetings and seminars, and connect members of the community who share similar experiences.

IMPORTANT SAFETY INFORMATION (cont’d)

What is the most important information I should know about TECVAYLI® (cont’d)?

How will I receive TECVAYLI®?

- TECVAYLI® will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in your stomach area (abdomen). Your thigh or another area of your body may be injected.
- See “What is the most important information I should know about TECVAYLI®?” at the beginning of this Important Safety Information for information about how you will receive TECVAYLI®.

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. It is important for you to be monitored closely for side effects during treatment with TECVAYLI®.
Support for caregivers

Caring for someone with relapsed or refractory multiple myeloma can be very overwhelming, but there are resources that can help

When caring for someone with multiple myeloma, you may need to provide them with both emotional and physical support. While it’s important to support them in their treatment journey, you are in this together and you need to find ways to support yourself as well.

Remember that you’re not alone; you have support

- Doctor and Healthcare Team
- Coworkers and Neighbors
- Janssen Compass® Care Navigator
- Family and Friends
- You

Being an available caregiver means also taking care of yourself

Here are some tips that you can use to care for yourself:

- Ask for help if you need it. Many caregivers look back and realize they had put too much on their plate and wish they had asked for more help
- Take care of your own health. Make sure you are eating well, getting some exercise, resting, and not neglecting your own medical care
- Be sure to make time to relax and to do things that are important to you
- Join a caregiver support group. Connecting with people going through a similar experience can let you know you are not alone and give you new ideas for coping
- Consider writing in a journal. Keeping a journal can help lessen negative thoughts and feelings you might have

Caregiving may take a toll on you, and you need breaks and support too.

Please read full Important Safety Information on pages 6-9, and full Prescribing Information, including Boxed WARNING, for TECVAYLI®.
A one-on-one support program designed for the person you care for

Once the person in your care’s doctor has decided that TECVAYLI® is right for the person you care for, a Janssen Compass® Care Navigator is just a phone call away! The person in your care can call us at 844-628-1234, Monday through Friday, 8:30 AM – 8:30 PM ET.

Once the person you care for is enrolled, a dedicated Care Navigator can help them find the resources they need, and that you may need too

Explore options that may be available to help the person in your care save on potential out-of-pocket medication costs

Whether they have commercial insurance or government-funded coverage—or even no insurance at all—we can help the person in your care find programs that may help them pay for TECVAYLI®.

Learn more about the person in your care’s cancer and their TECVAYLI® treatment

A Janssen Compass® Care Navigator will support and guide the person in your care as they start and continue treatment by providing ongoing education about TECVAYLI®.

Find resources for the person in your care’s practical and emotional needs while coping with cancer, and yours too

While the person you care for is on TECVAYLI®, they will work with their Janssen Compass® Care Navigator to discover tips, strategies, and resources for caring for themselves during treatment, help set goals for living with cancer, and connect with advocacy groups and a wider community of support.

Paying for TECVAYLI®

The person in your care’s out-of-pocket cost for TECVAYLI® is determined by their insurance coverage. Call a Janssen Compass® Care Navigator to receive personalized options to help the person in your care pay for their medication.

Here are a few of the options that may be available:

For Commercially Insured Patients: Savings Program

Eligible patients pay as little as $5 per dose of their TECVAYLI® medication. There is a limit to savings each year. The program does not cover the cost for the healthcare provider to administer their injections. Participate without sharing income information. See program requirements at tecvayli.janssencarepathsavings.com.

Call a Care Navigator to learn more about program requirements and enroll over the phone.

Other resources

A Care Navigator can be the person in your care’s guide to nonprofit organizations, patient advocacy groups, and state programs that may help with financial assistance.

Visit janssencompass.com to request a first call and learn more about how Janssen Compass® can be here for the person you care for. The person in your care can also call us at 844-NAV-1234 (844-628-1234), Monday through Friday, 8:30 AM – 8:30 PM ET.

Visit janssencompass.com to learn about other resources available to the person you care for.

Janssen Compass® is limited to education about the person in your care’s Janssen therapy, its administration, and/or their disease. It is intended to supplement your understanding of the person in your care’s therapy and is not intended to provide medical advice, replace a treatment plan from their doctor or nurse, or serve as a reason for them to start or stay on this medication.

Janssen Patient Assistance

Patient assistance from Janssen is available if they have commercial, employer-sponsored, or government coverage that does not fully meet their needs. They may be eligible to receive their Janssen medication free of charge for up to one year. They must meet the eligibility and income requirements for the Janssen Patient Assistance Program. See terms and conditions at PatientAssistanceInfo.com or call 833-742-0791.